The vaccine has been granted the National Registration Certificate for New Veterinary Drug and the production approval document number as well as the approval to be marketed as a national-level new veterinary drug of the second category from the Ministry of Agriculture (MOA), according to an official source.

This is the first major result of the Project of R&D on New Diagnostic Technology and New Vaccines for Major Swine Diseases, a key specialized project on science and technology of the Province during the Eleventh Five-Year Plan period implemented by Luoyang Pu-Like Bio-Engineering Company Limited.

According to the introduction, this PCV vaccine independently developed by China could create direct economic benefits of over one billion yuan and reduce the loss from the disease by over 36 billion yuan during the four years' protection period, and help the swine industry save vaccination expenses of three billion yuan each year.

PCVD is globally recognized as a major disease that jeopardizes the swine industry, and also one of the three major diseases that do harm to China's swine industry.

Yang Hanchun, Director and Chief Scientist of the national research office for disease control in the modern swine industry and Professor of China Agricultural University said: "PCVD is one of the major diseases that affect China’s swine industry; and effective vaccination is crucial to control the spread of PCV."

Further Reading

-

Find out more information on Post-Weaning Multisystemic Wasting Syndrome (PMWS) by clicking here.